

TAIWAN

Your Best Partner In Asia



2022 BIO International Convention, June 13-16, 2022
Taiwan Pavilion Booth 3323

Your Best Partner in Asia!

As the center of Asia-Pacific region, Taiwan is not only a crucial link between Europe, America, Japan and the emerging Asia-Pacific markets, but also a preferred location for multinational companies to establish their regional headquarters. In addition, Taiwan's government actively promotes the precision health industry and combines information communication technology competence to realize interdisciplinary collaboration to reach the goal, a vision of whole-life health, in 2030.

Strengths:

- Asia-Pacific Hub
- Abundant Government Resources
- Compliance with PIC/s GMP, ISO13485 & GMP
- Comprehensive Clusters Infrastructure
- High-Quality Clinical Research
- Well-Protected Intellectual Property System & International Regulatory Compatibility
- Friendly Investment, Fundraising & Financing Environment


Comprehensive bio-clusters:

- Northern Taiwan
 1. Drugs (Discovery, Biologics, Pharmaceuticals)
 2. Medical Devices (Diagnostics, Medical Electronics, IVD, Medical Imaging)
- Central Taiwan
 1. Drugs (Pharmaceuticals, Vaccines)
 2. Medical Devices (Rehabilitation Devices, Minimal Invasive Surgical Devices)
- Southern Taiwan
 1. Drugs (API)
 2. Medical Devices (Implantable Devices, Minimal Invasive Surgical Devices)
 3. Herbal Medicines, Functional Foods, Animal Breeding and Vaccines

Exhibit Hall | Floor Map



Taiwan Pavilion No.3323



Events during BIO

Event : Taiwan Pavilion Opening Ceremony & Happy Hour

Time : 16:00-17:00, June 14

Venue : Taiwan Pavilion

Event : Appreciation Party

Time : 17:30-20:30, June 14

Venue : Grand Ballroom, Marriott Marquis San Diego Marina


Event : Global Innovation Hub - Taiwan: Ideal Partner for Precision Health in Asia Pacific

Time : 14:30-15:00, June 15

Taiwan Pavilion Booth 3323 | Floor Map

- | | |
|----|--|
| 1 | Far East Bio-Tec Co., Ltd.
BRIM Biotechnology, Inc. |
| 2 | QT Medical, Inc.
TaiHao Medical Inc. |
| 3 | Agricultural Technology Research Institute |
| 4 | Adimmune-Animmune |
| 5 | TaiMed Biologics Inc. |
| 6 | OriGem Biotech. |
| 7 | Alar Pharmaceuticals Inc. |
| 8 | United BioPharma, Inc. |
| 9 | TLC BioSciences |
| 10 | EirGenix, Inc. |
| 11 | Taipei City Government |
| 12 | Instant NanoBiosensors Co., Ltd.
Bened Biomedical Co., Ltd. |
| 13 | Agricultural Technology Research Institute |
| 14 | TFBS Bioscience, Inc. |
| 15 | Ascendo Biotechnology Inc. |
| 16 | PharmaEssentia Corp. |
| 17 | Taiwan Bio Industry Organization |
| 18 | ACRO Biomedical Co., Ltd. |
| 19 | OBI Pharma, Inc. |
| 20 | Formosa Laboratories, Inc. |
-

Taiwan Pavilion Booth 3323 | Floor Map



Taiwan Pavilion Booth 3323 | Floor Map

21 **AcadeMab Biomedical Inc.**
Anbogen Therapeutics, Inc.

22 **Calgent Biotechnology Co., Ltd.**
ImmunAdd Inc.

23 **AHEAD Medicine**
APrevent Medical Ltd.

24 **Pharmasaga Co. Ltd.**
PrecisemAb Biotech Co., Ltd.

25 **CancerFree Biotech Ltd.**
Protect Biotech Incorporation

26 **Deep01 Ltd.**
FaceHeart Corporation

27 **Molsentech**
SoundJet Medical, Inc.

28 **Academia Sinica**
Biomedical Translation Research Center,
Academia Sinica

29 **Agricultural Technology Research Institute**


30 **Medical and Pharmaceutical Industry**
Technology and Development Center

31 **Industrial Technology Research Institute**

32 **National Health Research Institutes**

33 **Development Center for Biotechnology**

Taiwan Pavilion Booth 3323 | Floor Map



Content

Biologics

AcadeMab Biomedical Inc.	01
ACRO Biomedical Co., Ltd.	02
Ascendo Biotechnology Inc.	03
EirGenix, Inc.	04
Far East Bio-Tec. Co., Ltd. (FEBICO)	05
OBI Pharma, Inc.	06
PharmaEssentia Corp.	07
PrecisemAb Biotech Co., Ltd.	08

Biotech (incl. agriculture)

Adimmune-Animmune	09
Bened Biomedical Co., Ltd.	10
BRIM Biotechnology, Inc.	11
Calgent Biotechnology Co. Ltd.	12
OriGem Biotech.	13
Protect Biotech Incorporation	14
TLC BioSciences	15

Contracted Services (incl. CRO, CDMO)

CancerFree Biotech Ltd.	16
Formosa Laboratories, Inc.	17
TaiMed Biologics Inc.	18
TFBS Bioscience, Inc.	19
United BioPharma, Inc.	20

Medical Device

Molsentech	21
QT Medical, Inc.	22
SoundJet Medical, Inc.	23

Precision Health

AHEAD Medicine	24
Anbogen Therapeutics, Inc.	25

Content

Small Molecule Drugs

Alar Pharmaceuticals Inc.	26
ImmunAdd Inc.	27
Pharmasaga Co. Ltd.	28

Smart Health

APrevent Medical Ltd.	29
Deep01 Ltd.	30
FaceHeart Corporation	31
Instant NanoBiosensors Co., Ltd.	32
TaiHao Medical Inc.	33

Government

Academia Sinica	34
Biomedical Translation Research Center, Academia Sinica	35
Central Taiwan Science Park	36
Council of Agriculture, Executive Yuan	37
Department of Academia-Industry Collaboration and Science Park Affairs, Ministry of Science and Technology	38
Hsinchu Biomedical Science Park	39
Ministry of Health and Welfare	40
Ministry of Science and Technology	41
Southern Taiwan Science Park Bureau, MOST	42
Taiwan Stock Exchange	43
Taipei City Government	44

Non-profit Research Organization

Agricultural Technology Research Institute	45
Development Center for Biotechnology	46
Industrial Technology Research Institute	47
Medical and Pharmaceutical Industry Technology and Development Center	48
National Health Research Institutes	49
Taipei Exchange	50
Taiwan Bio Industry Organization	51
Taiwan External Trade Development Council	52



Main Products / Services / Pipelines & Platforms

AM-928 & AM-168 therapeutic antibodies for oncology field

COVID-19 therapeutic antibody

- Mouse hybridoma antibody platform
- Phage display human scFv library platform
- Single B cell antibody screening platform
- Human antibody mouse platform

Business Interests

- In-/Out-Licensing
- Collaborative R&D
- Contracted antibody development service

Contact Information

Name Miles Yeh
Position Manager
Tel +886-2-2789-1212 #810
Email miles.yeh@academab.com



Main Products / Services / Pipelines & Platforms

- ABCcolla® Collagen Matrix-The porous collagen biomaterial absorbs wound exudates and maintains an moist environment conducive to healing.
- ABCcolla® Bone Graft - It is intended for filling and augmentation of bone voids or gaps during orthopedic and dental surgeries. It facilitates cell attachment and improves bone regeneration and neovascularization.
- ABCcolla® Collagen Ophthalmic Matrix - It is intended for cornea transplantation in replacement of human donated cornea.
- ACROTERM Tissue & Organ Scaffolds - Native collagen scaffolds derived from porcine tissues and organs, decellularized by supercritical CO₂ extraction technology. All scaffolds retain their native ECM structures and are biocompatible for stem cell culture and tissue engineering research.
- ACROTERM Tissue & Organ Scaffold Powders - Native collagen scaffold powders derived from porcine tissues and organs, decellularized by supercritical CO₂ extraction technology. All scaffold particles retain their native ECM structures, suitable for 3D bioprinting research purposes.

Business Interests

- Distribution
- ODM/OEM
- R&D Collaboration
- Licensing

Contact Information

Name Dora Hsieh
Position Special Assistant to CEO
Tel +886-7-695-5569 #233
Email dora@acrobiomedical.com



Main Products

ASD141

- First-in-the-class innate immune checkpoint inhibitor
- Break the bottleneck of cancer immunotherapy through preventing a novel regulatory ligand to induce innate cold in TME
- Significantly enrich the infiltration of functional APCs and neoantigen specific CD8 in TME
- Very synergetic with effector cell level of ICIs (antiPD1/PDL1/CTLA4)
- Dramatically ameliorate the acute injection reactions when combined with antiCTLA4
- Excellent tolerability in pharmacology and PK studies
- Under preclinical development and plan to submit IND soon.

NanoCherub®

- A versatile ElectroKinetic nanocomplex antigen adjuvant/delivery platform for vaccine development

ASD253

- Therapeutic vaccine for HBV achieved 100% functional cure pharmacologically (HDI /AAV models).
- No LFT abnormality in both animal models.
- Under preclinical development

ASD254

- RBD/RBM based subunit protein vaccine of Covid-19
- Nonpolarized Th1/Th2 immunogenicity
- Long lasting protection and maintain good protection to VOCs.
- Under preclinical development

Business Interests

We are seeking out-licensing opportunities and co-developing our assets or R&D collaboration:

- ASD141, first in the class innate immune checkpoint inhibitor
- ASD253, therapeutic vaccine for hepatitis B
- ASD254, RBD based subunit protein, preventive vaccine of Covid-19

Contact Information

Name Teresa Chou
Position VP
Tel +886-986-291-144
Email contact@ascendobiotech.com



Main Products / Services / Pipelines & Platforms

One-stop Biologics CDMO in mammalian and microbial systems

- From DNA to small-scale and commercial-scale GMP manufacturing (DS & DP)
- Biosimilars development and in/out-licensing
- CRM197 for vaccine formulation & HRV 3C Protease
- COVID-19 Vaccine DS & Rapid Test

Business Interests

- Biologics CDMO- mAb, bispecific antibody, ADC, recombinant protein/peptide, enzymes, plasmid DNA, RNA and viral vector
- Biosimilars in/out-licensing
- Biosimilar co-development
- M&A- Biologics CDMO or CRO

Contact Information

Name Albert C. Lin
Position Business Development Director
Tel +886-930-060-588
Email albert.chlin@eirgeix.com



Main Products

- Dietary Supplement: Microalgae derived health food
- Diagnostic Reagents: fluorescent protein, Isothermal PCR enzyme matrix
- Regenerative medicine: Microalgae derived cell growth medium; Single polymer, SHWE-HSB, used for Stem cell attachment and growth in cell culture
- New drug development: Liver derived disease
 1. FB-1603 would file the IND in 2022 for liver damage relief.
 2. FB-1807 is a new small entity with specific cytotoxicity on TGF-beta activated rat and human hepatic stellate cell. The raw material of FB-1807 was previously investigated in two human studies, and found the fibrosis relief with albumin improving in 28 weeks.

Business Interests

- New drug development: We are seeking out-licensing or co-development opportunities on our drug candidate.
- Regenerative Medicine: We provide the critical materials for stem cell culture.

Contact information

Name Lilien Chen
Position Research Scientist
Tel +886-2-2655-8198
Email rdrad001@febico.com.tw



Main Products / Services / Platforms

OBI Pharma, Inc., is a Taiwan biopharmaceutical company publicly-listed on the Taipei Exchange (TPex ticker: 4174). OBI's mission is to develop and license novel therapeutic agents for unmet medical needs against cancer targets such as Globo Series (incl. Globo H, SSEA3, SSEA4) and AKR1C3. Globo Series and AKR1C3 are highly expressed in cancers of unmet need including Breast, Ovarian, Gastric, Lung, Liver Prostate and Esophageal. The company's novel first-in-class oncology portfolio includes:

- Adagloxad Simolenin (formerly OBI-822; Globo H cancer vaccine)
- OBI-888 (Globo H mAb)
- OBI-999 (Globo H ADC)
- OBI-866 (SSEA4 cancer vaccine)
- OBI-3424 (small-molecule prodrug targeting AKR1C3 enzyme)

Business Interests

OBI is seeking out-licensing opportunities to expedite the clinical development of our pipeline products. OBI is also looking to in-license novel anti-cancer therapies to compliment and strengthen our pipeline.

Contact information

Name	Tod Lauerma
Position	Executive Director, Business Development
Tel	+1-619-537-7698 #111
Email	tlauerma@obipharmausa.com



Main Products

Besremi (ropeginterferon alfa-2b)

Business Interests

Licensing

Contact Information

Name Dr. Ko-Chung Lin

Position CEO

Email kochung_lin@pharmaessentia.com



Main Products/ Services / Platforms

PrecisemAb is committed to developing safer antibody therapy with higher efficacy. Our disease-directed Universal Antibody Lock™ is an autologous masking structure on the binding site of an antibody that allows antibody drugs to take effect only in diseased areas, making antibody treatment extraordinarily safe.

Compared to competitors, our Lock-antibody

- has a higher masking ability and can be fully activated in the diseased area
- has low immunogenicity
- has a prolonged serum half-life, leading to higher therapeutic efficacy
- prevents interfere effect of anti-drug antibody
- needs only 5 months for Lock-design and function test

Business Interests

- Customized Antibody Lock™ design service : Antibody lock design and test for your antibody.
- PrecisemAb developed antibody out-licensing : Lock-EGFR, Lock-PD-1, Lock-CTLA4, Lock-TNF α , Lock-4-1BB, Lock-IL-1 β
- Co-development of lock-antibody drugs : Developing from Antibody Lock design to preclinical experiments.

Contact Information

Name YunChi Lu, PhD.
Position CEO
Tel +886-916-822-487
Email yunchi.lu@precisemab.com





Main Products/ Services

- Season Influenza Vaccine
- CMO & CDMO Service (PFS fill/finish, Bacular Virus Insect Cell System, Egg Base System, Cell Culture System)
- Animal Vaccine Development

Business Interests

- CMO & CDMO Service
- Animal Vaccine Development

Contact Information

Name Albert Hung

Position President of Animmune Deputy Chief Operating officer of Adimmune

Tel +886-922-655-461

Email albert_hung@adimmune.com.tw



Main Products/ Services

- Functional probiotic raw material
- Private label service entailing customized probiotic formulation finished products (containing our own patented strains)
- Assistance with product design, registration, and promotion
- Development of live biotherapeutic products
- Clinical research collaboration

Business Interests

- Distribution
- ODM/OEM
- Licensing out

Contact Information

Name Alain Delpy
Position Director of International Business Development
Tel +886-2-2511-1122 #118
Email alain.delpy@benedbiomed.com



Main Products / Services / Pipelines & Platforms

BRIM is a clinical-stage company developing novel peptide treatments for hard-to-treat diseases. BRIM's first-in-class assets are based on its innovative stem cell regenerative PDSP technology platform, which has the potential to be effective in multiple therapy areas and indications:

- BRM421 - a phase 3 ready drug for Dry Eye Syndrome
- BRM424 - a phase 2 ready orphan drug for Neurotrophic Keratitis
- BRM521 - a preclinical drug for Osteoarthritis(OA)

Business Interests

We are looking for investment opportunities for our portfolio and seeking out-licensing or co-development partnerships for the following assets:

- BRM421 - a phase 3 ready drug for Dry Eye Syndrome,
- BRM424 - a phase 2 ready orphan drug for Neurotrophic Keratitis,
- BRM521 - a preclinical drug for OA,
- BRM132 - a phase 1 drug for NHL (non-Hodgkin lymphoma).

Contact Information

Name Yichun Maria Chen
Position VP of Business Development
Tel +886-2-2659-8586 #110
Email yichun.chen@brimbiotech.com

Name Yilun Chiang
Position Business Development Manager
Tel +886-2-2659-8586 #120
Email yilun.chiang@brimbiotech.com



Main Products / Services / Pipelines & Platforms

Our main product, CAL056:

- an orally administrated, anti-cancer drug, modulated proteasome pathway, with high selectivity of cytotoxicity and anti-proliferation activity toward cancer cells.
- CAL056 has shown tumor growth inhibition in various animal models including colorectal cancer, lung cancer, pancreatic cancer, breast cancer, bladder cancer, pancreatic cancer, multiple myeloma, and acute myeloid leukemia (AML). Besides, CAL056 also shown great potential in inflammation related disease such as lung fibrosis.

Advantages:

- With the high selectivity of cytotoxicity and anti-proliferation activity toward cancer cells, CAL056 expresses a broad therapeutic window which largely enhances the safety of treatment.
- CAL056 shows relatively little side effects compared to other current commercial available products targeting ubiquitin proteasome pathway, such as Bortezomib.
- As an oral anti-cancer drug, CAL056 owns a good oral bioavailability.

Business Interests

- CALGENT primarily focuses on the process from preclinical to clinical proof of concept (PoC) during the drug development value chain. CALGENT primarily targets highly novel projects with new molecular entities (NME) and niche technology platforms, in-licensing them from or partnering with academic institutions and biotech or pharma companies, both locally and internationally. Projects are selected based on their novelty as a drug target or platform technology for diseases where there are unmet medical needs.
- Upon reaching the clinical PoC, CALGENT will out-license or partner with the best-suited third party to continue development through market approvals and commercialization, maximizing profit through royalty, milestones, or profit sharing.

Contact Information

Name Alice Yang
Tel +886-2-2732-2782 #111
Email alice21@calgent.com



Main Services

- Single cell isolation capture and culture chip
- Hanging Drop MicroCellChip for 3D cell culture
- Microfluidic Biochip integration: Design/Tooling/Fabrication
- Design and Production of Lab's consumables

Business Interests

- Distributors with Global Channels
- Collaborative R&D/Fabrication in microfluidic field
- Cooperation in design and production of lab's consumable items

Contact Information

Name Eric Chao
Position Manager
Tel +886-937-848-509
Email eric@origembitech.com

Main Products

Companion animal immunotherapy drugs

Business Interests

- Out-Licensing: finds partners to bring our immunotherapy drugs to the markets in US, EU, China, etc.
- Collaborative R&D: codevelop DNA/mRNA immunotherapy drugs for animal cancer, infection disease, chronic diseases, etc.

Contact Information

Name Haolin, Sung
Position CEO
Tel +886-2-2727-6289
Email haolinsung@protectvac.com



Main Products / Services / Pipelines & Platforms

TLC BioSciences is a clinical-stage specialty pharmaceutical company developing novel nanomedicines that maximize the potential of its proprietary LipAD[®] lipid-assembled drug delivery platforms.

LipAD[®] Platforms:

- BioSeizer[®] - sustained release technology for biologics and/or small molecules
- NanoX[®] - tissue-targeted liposomal delivery with an ionic gradient for active drug loading, proven in 2 approved drugs

Pipeline:

- TLC599 (osteoarthritis pain)
- TLC590 (postsurgical pain)
- TLC399 (macular edema)
- TLC178 (advanced malignancies / soft tissue sarcoma)
- Ampholipad[™] (systemic fungal infections)
- ISPM19 (COVID 19 / respiratory diseases)

Business Interests

- Out-Licensing
- Collaborative R&D
- CMO

Contact information

Name Ms. Lindsey Yang
Position Specialist, President's office
Tel +886-2-2655-7377
Email lindsey@tlcbio.com



Main Products / Services / Pipelines & Platforms

E.V.A.[®] (Ex Vivo Avatar) combines 3D scaffolds and AI image recognition to facilitate tumor cell proliferation steadily. With only a 20ml blood sample, it can grow cancer cells to form an organoid model rapidly that can help new cancer drug development companies to validate the drug suppression effect on tumor cells from real patients and screen for the clinical trial candidates.

Moreover, E.V.A. also can help doctors and patients determine the best treatment strategy when fighting cancer, particularly late-stage cancer. There are other potential applications of E.V.A. including cell therapy, cancer vaccines, etc.

Business Interests

- Drug development collaboration
- Lab space collaboration
- Strategic partner (clinic or CRO)
- POC
- Distributor

Contact Information

Name	Kevin
Position	CSO
Tel	+1-628-283-9122
Email	kevin@cancerfree.io



Main Products / Services / Pipelines & Platforms

- PIC/S GMP and GDP compliance
- API development and manufacturing services
- ADC development and manufacturing services
- ADC payload-linker screening platform
- Formulation development
- Injectable filling services
- Packing, labelling, and delivering services
- Regulatory services
- API and Injectable products sales and licensing-out

Business Interests

- Injectable products licensing-out.
- API products selling
- API, ADC, and injectable CDMO services.

Contact information

Name Tom Tseng
Position Manager, FDF&CDMO Services in Marketing&Sales
Tel +886-3-324-0895 #277
Email tomtseng@formosalab.com



Main Products / Services / Pipelines & Platforms

TaiMed Biologics was founded in 2007 and has devoted itself as a leading biopharmaceutical developer and manufacturer of innovative biologics drugs. TaiMed has developed a first-in-class anti-HIV antibody drug ibalizumab (Trogarzo®) which the US FDA and EMA approved in 2018 and 2019, respectively.

Leveraging our experience developing Trogarzo® and other novel, long-acting anti-HIV monoclonal antibodies in the pipeline, TaiMed has also become a Contract Development and Manufacturing Organization (CDMO) offering manufacturing solutions that will enable partners to discover, develop and manufacture biologics from the bench to market. We strive to ensure that our clients' projects are treated as our own with the same high standards with respect to quality, cost and logistical requirements.

Business Interests

- Out-Licensing novel, long-acting anti-HIV monoclonal antibodies.
- Contract Manufacturing
- Contract Development and Manufacturing

Contact Information

Name Glory Lin | Taiwan (CDMO)
Position Senior Manager, Manufacturing and Technology
Tel +886-3-621-2355 #210
Email cdm0@taimedbio.com

Name Jonathan Ho | United States (Out-licensing)
Position Senior Director, Business Development & Alliance Management
Tel +1-917-803-7770
Email jho@taimedbio.com



Main Products / Services / Platforms

TFBS Bioscience Inc. is a certified and leading GMP Viral Vector Contract Development and Manufacturing Organization in Asia-Pacific and the first specialist viral vector provider in Taiwan. We have a wide array of businesses as follows:

- GMP-compliant LV, AAV viral vectors production
- Preclinical animal safety testing including tumorigenicity, immunogenicity, PK, bio-distribution, pharmacology, and toxicity
- Cell bank characterization for CHO, 293T, and stromal mesenchymal stem cells
- QC testing for cell banks, biologics, vaccines, or cellular therapy products.
- GMP/GLP grade sterility study and mycoplasma detection
- Bacterial bank characterization for E.coli

Business Interests

- The companies/institutes who concern with
 1. High quality in viral vector manufacturing
 2. Customized service by effective communication.
- The reliable companies/institutes willing to be TFBS' to expand the business.

Contact Information

Name Shao Hua Lo
Position Director
Tel +886-2-2694-7888 #121
Email service@tfbsbio.com



Main Products / Services / Pipelines & Platforms

United BioPharma (UBP), as a biopharmaceutical company, we are focusing on CDMO services and developing innovative therapeutic monoclonal antibodies.

Our CDMO services

- UBP is dedicated to the development and commercialization of biologics.
- UBP supported the development projects from phase 1 to phase 3 clinical trials located in the US, China, and Asia.
- UBP achieved 10 g/L in the upstream process and more than 80% recovery rate in the downstream process.
- UBP established proprietary platforms to decrease fucosylation or prolong protein half-life.
- UBP has manufacturing sites in Taiwan and China to support global supply from preclinical to commercial and to backup each other. The total capacity is about 10,000L.

Our advanced production pipelines

- UB-421; an anti-CD4 mAb to treat HIV infection
- UB-621; anti-HSV mAb to treat recurrent genital herpes
- UB-221; anti-IgE mAb to treat chronic spontaneous urticaria (CSU)

Business Interests

In-/Out-Licensing , CDMO

Contact information

Name Sunny Wang
Position Manager
Tel +886-908-501-621
Email sunny.wang@unitedbiopharma.com



Main Products / Services/ Pipelines & Platforms

- A 100% electrical-based disease detection platform powered by the Bio-FET technology.
- A label-free disease detection platform offers real-time, high accurate, user-friendly, and ultrahigh-sensitive (10^{-16} M for nucleic acid & 10^{-15} g/ml for proteins) detections.
- Biosensors are modified with biomarkers on the surface as probes to catch detection targets in samples, causing immediate charge changes in electrical signals for analyzers to read and generate detection results.
- The Bio-FET-enabled platform is widely expandable to different applications and able to detect both nucleic acid and protein.
- The development time for a new biosensor assay is as short as 3 months.

Business Interests

- Strategic Partnership
- Out-Licensing
- Collaborative R&D
- Product Joint Development
- Distribution Selling

Contact Information

Name ShihYu Yeh
Position Business Planning Lead
Tel +886-2-2783-5173
Email syieh@molsentech.com

James Fan
Executive Assistant to CEO
+886-2-2783-5173
syfan@molsentech.com



Main Products / Services

World's most compact 12-lead ECG System.

The PCA 500 is a complete ECG solution that simplifies and streamlines the 12-lead ECG test. With seamless integration of state-of-the-art technologies: a super-compact recorder, patented prepositioned electrode strips, user-friendly apps for mobile devices, and HIPAA-compliant cloud, a hospital-quality 12-lead ECG test can be completed in 3 minutes by anyone, anytime, anywhere. QT Medical offers the perfect cardiac care solution for ECG needs in the pandemic. It is medical grade, cleared by the FDA and CE marked.

Efficient

Reduces leads placement time by almost 70%! Without complex wires, our patented pre-positioned electrode simplifies the 12 lead ECG test. By applying QT Medical ECG electrode strips with PCA 500, the setup time can be 70% faster.

Simple and Accurate

With the disposable patented pre-positioned electrodes, there's a lower risk of infection, without the need for technicians, anyone can apply with minimal training required, and decreased errors from lead reversals and misplacements.

Secured Cloud ECG Management

All test results are managed in the Cloud! All ECG data are encrypted and transferred to the HIPAA & GDPR compliant QT Cloud, and ECG report is available in PDF and EMR ready.

Business Interests

Distribution, Collaborative R&D, Project Collaboration, Cross-Industry Alliance.

Contact information

Name Shirley Wang
Position Director of Sales and Marketing
Tel +1-909-303-0007
Email marketing@qtmedical.com



Main Products / Services

- SoundJet Medical develops an innovative ultrasonic thrombolytic device for the treatments of pulmonary embolism (PE) and deep vein thrombosis (DVT).
- The core technology of SoundJet Medical is called VorteSonic, which applies ultrasonic vortex (ultrasonic tornadoes) to achieve high performance in thrombolysis.

Business Interests

- Out-Licensing
- Collaborative R&D
- CDMO
- CRO

Contact information

Name Chun-Yen Lai
Position CEO
Tel +886-921-357-366
Email chunyen.lai@gmail.com



Main Products / Pipelines

AHEAD delivers on-demand insights by replacing human visual interpretation of cell-level data with AI and machine learning. As the software intelligence layer between machine-generated cell-level details and humans, the AHEAD platform offers AI/ML enhanced accuracy, 10X-20X faster results, and 3-6X lower costs. Low cost, on-demand insights, and higher productivity enable AHEAD to relieve bottlenecks and enable global availability.

Business Interests

- In-/Out-Licensing
- Collaborative R&D

Contact information

Name	Yu-Fen Wang
Position	CEO
Tel	+510-380-5920
Email	andrea.wang@aheadmedicine.com



Main Products / Pipelines

Anbogen Therapeutics is a clinical stage precision oncology company developing first/best-in-class personalized therapeutics for the treatment of solid tumors and blood cancers, we are committed to bring the innovation to fight serious illness and develop treatments for the patients.

- **ABT-101:** ABT-101 is a tyrosine kinase inhibitor targeting HER2 exon20 insertion. The particular mutation is mainly found in a subset of non-small cell lung cancer. Currently we are conducting A phase 1b/2 study for ABT-101 in multiple sites.
- **ABT-301:** ABT-301 is an HDAC inhibitor with promising clinical and pre-clinical data indicates that ABT-301 has an exceptional safety and drug exposure profile in human. Several cancer treatment modalities can be enhanced with the combination of ABT-301, which include chemo-radiation therapy prior to surgery for rectal cancer, EB virus positive cancers or lymphoma, castration-resistant prostate cancer, and checkpoint blockade inhibitor therapy.

Business Interests

Seeking licensing partnering opportunity

Contact information

Name Angus Wu
Position VP, Business Development
Tel +1-858-319-9524
Email angus.wu@anbogen.com



Main Products / Pipelines

- ALA-1000, a 1-month/ 3-month released buprenorphine injectable for opioid use disorder/ chronic pain
- ALA-2000, a sustained release naltrexone injectable for alcohol/ opioid use disorder
- ALA-3000, a sustained release ketamine injectable for treatment-resistant depression
- ALA-4000, a sustained release apomorphine injectable for Parkinson's disease

Business Interests

Out-Licensing, Collaborative R&D, Clinical Trial

Contact information

Name Renee Liang
Position R&D Manager
Tel +886-4-2463-7115
Email alar@alarpharm.com



Main Products / Services/ Pipelines & Platforms

- ImmunAdd, Inc., is a privately-held biopharmaceutical company on a mission to improve health through advances in adjuvant design and formulation.
- We developed next-generation saponin adjuvants and have demonstrated safety and efficacy in vaccines.
- Our lead adjuvant, IA05, is a rationally designed analog of the saponin adjuvant QS-21. It is a synthetic small molecule and does not rely on the Quillaja tree. IA05 elicits immune responses comparable to or better than QS-21 and is well tolerated, has higher stability, and has lower toxicity.
- With IA05 as the foundation, ImmunAdd is designing adjuvant platforms to deliver a variety of immune-related therapies.

Business Interests

- Out-Licensing, Collaborative R&D
- Collaborative R&D

Contact information

Name Pi-Hui Liang
Position Acting CEO
Tel +886-932-187-796
Email phliang@immunadd.com



Main Products / Pipelines

- Pdia4 expressed specifically in β cells, and increases in response to excess nutrient. Pdia4 positively regulated β cell death, dysfunction, and ROS production.
- Using molecular docking and modification, PS-001 was identified as a Pdia4 specific inhibitor.
- PS-001 can prevent β cell dysfunction and death via reduction of ROS induced by nutrient. Furthermore, PS-001 alone or combined with other diabetes drug can stabilize blood glucose and reverse diabetes in mice.
- PS-001 is a first-in-class drug which can treat and reverse diabetes through a novel mechanism.
- The US IND of PS-001 had been approved in 2022Q1, and the Phase I clinical trial will be launched in 2022Q3.
- The Phase II trial will be completed in 2025, and will be licensed out to global pharmaceuticals
- The PS-002 (same API of PS-001) is potential to treat Type I diabetes

Business Interests

We are looking for collaboration with and out-licensing to global pharmaceuticals

Contact information

Name Tzung-Yan Chen
Position COO
Tel +886-2-2653-8670 #2044 / +886-937-457-634
Email zong770115@gmail.com



Main Products / Pipelines

AiSpeak uses AI technology to help patients with motor speech disorders to regain normal communication capability and life quality. Feature of AiSpeak includes:

- machine learning technology which enables continuous improvement of recognition accuracy and speech intelligibility.
- real-time dysarthria speech recognition and conversion.
- customized needs with individualized training and programming.
- speech conversion without limitation of vocabularies.
- connection to the Internet of Things (IoT) for broader applications.
- continuous accumulation of big data of dysarthric speech with steady enhancement of speech intelligibility.
- AiSpeak can also recognize, diagnose, and monitor conditions of a neurological disease based on the changes and variations of acoustic characteristics from patients.

Business Interests

AiSpeak can provide B2C services for individuals or B2B by integrating with other ready to market commercial products or solutions or expand its usage and language through co-development or licensing.

Contact information

Name Mark Chang
Position COO and CTO
Tel +886-2-2888-1107
Email mark@apreventmed.com



Main Products

DeepCT is the world-leading AI-powered brain CT abnormalities detection and quantification system. It detects brain bleeds, fractures, midline shift, and calculates ICH Score automatically.

Our AI makes doctors more efficiently in the medical process:

- For Neurosurgeons - help to evaluate patients
- For Emergency Physicians - help to triage patients
- For Radiologists - help to generate reports

Business Interests

- Looking for medical devices distributors to carry our AI system to improve healthcare quality
- Looking for hospitals for research collaboration
- Looking for investors

Contact information

Name Vicky Chou
Position Executive assistant
Tel +886-2-2365-9959
Email admin@deep01.com



Main Products

FaceHeart Corp. improves human health through its proprietary video-based rPPG solutions, FaceHeart Vitals™ SDK, empowers home-use/personal devices to measure heart rate, heart rate variability, blood pressure, respiration rate, oxygen saturation and stress index seamlessly and remotely.

FaceHeart Vitals™ SDK is the core component of FaceHeart products, it provides application developers with a series of software modules, allowing them to easily incorporate the contactless vital signs measurement solution into their desired applications.

FaceHeart Vitals™ SDK evolves to support Android, iOS, Windows, and Linux and can be easily integrated into hardware devices equipped with an adequate single camera.

- 76M validated records via clinical trials
- Application integrations via SDK/API
- Android, iOS, Windows & Linux enabled
- Vital sign measurements via edge computing

Business Interests

- Mobile Health App Developers
- Smart Healthcare Professionals
- Telemedicine Practitioners

Contact information

Name FaceHeart Marketing
Position Marketing Division
Tel +886-3-659-1088
Email marketing@faceheart.com



Main Products

The Product

- Instant NanoBiosensors (INB) is an innovative company which has developed ultra-sensitive portable immunoassay platform with over 35 patents based on FOPPR (fiber optical particle plasmon resonance) sensing technology and IN-Chip (auto-flowing microfluidic chip) technology enables customers to reliably detect protein biomarkers in extremely low concentrations in blood, serum and other body fluids.
- Through this platform, INB is applying developed biomarkers which have already translated from preclinical safety assessment to clinical utility in the neuroscience markets for life science research, diagnostics, early screening, monitoring and prognosis.

Core Technology

- Patented FOPPR (Fiber Optic Particle Plasmon Resonance) and IN-Chip (auto-flowing microfluidic chip) technologies.

Business Interests

Patented FOPPR (Fiber Optic Particle Plasmon Resonance) and IN-Chip (auto-flowing microfluidic chip) technologies.

Contact information

Name Suri Huang
Position Marketing Director
Tel +886-2-2653-8655 / +886-912-619-006
Email info@instantnano.com



Main Products / Pipelines

BU-CAD™

BU-CAD™ is a software application indicated to assist trained interpreting physicians in analyzing the breast ultrasound images of patients with soft tissue breast lesions suspicious for breast cancer who are being referred for further diagnostic ultrasound examination.

BR-Viewer™

BR-Viewer supports ABUS images from SIEMENS, GE and other vendors (DICOM format), and supports our computer-aided detection method to detect breast lesions in thousands of images. Also, it provides marker annotation and 3D manipulation to assist physicians in reviewing. The reporting system using BI-RADS lexicons can generate PDF, structured reports for each study. Besides, users of WorkstationOne™ can add BR-Viewer as a plug-in for reviewing ABUS images.

BR-FHUS Navigation™

BR-FHUS Smart System is a breast screening solution for handheld ultrasound. It contains two subsystems, Navigation and Viewer. BR-FHUS Navigation can assist radiologists in scanning. During the scan, the scanning routes and 2-D ultrasound images can be tracked and recorded to provide quality assurance, and also the probe position (clock and distance from nipple) and the suspicious lesions are recorded and alerted in real time.

BR-FHUS Viewer™

BR-FHUS Viewer assists physicians in reviewing a series of 2-D ultrasound images recorded by BR-FHUS Navigation. It supports our computer-aided detection method to detect breast lesions in the recorded images to improve diagnostic efficiency.

Business Interests

- Integrate with AI marketplace
- To cooperate with Distributor of each region and Ultrasound machine manufacturers
- Seeking for Strategic alliances partner to help TaiHao become the AI leader
Partners to Increase the sales of our products in the US
- Medical resources · including Hospital & Clinical in the US .

Contact information

Name TaiHao Medical Inc.
Tel +886-2-2736-5679
Email Sales@taihaomed.com



Main Products / Services / Pipelines & Platforms

Academia Sinica has three Divisions (Mathematics and Physical Sciences, Life Sciences, and Humanities and Social Sciences) to fulfill the following goals: There are three central objectives at Academia Sinica:

- Achieve global peaks of excellence;
- Fulfill social responsibilities in crucial areas; and
- Attract and cultivate top talent. We aspire to contribute to society from an academic perspective by targeting key issues and nurturing research talent to achieve excellence.

Business Interests

- Research cooperation
- Technology transfer.

Contact information

Name	Hong-Zhang Chen
Tel	+886-2-2787-2556
Email	jameschen@gate.sinica.edu.tw



Main Services

- Solicit Biomedical Translational Projects - BioTRec solicits the most promising proposals for projects that seek to translate biomedical technologies from basic research to clinical application.
- Construct a Strong Biotech Ecosystem - An important mission of BioTRec is to stimulate interdisciplinary collaboration between academia, industry and government agencies in order to enhance the international competitiveness of new drug development at NBRP.
- Develop Biotech Talent - To foster an entrepreneurial mindset and develop business skills for biotech start-ups.
- Integrate and deploy research capacity for emerging infectious diseases - Through the long-term establishments of RG2/RG3 infectious biomaterials libraries and infectious animal models, accumulation of research capacity, and cultivation of talented researchers and specialists for infectious disease prevention and control, the EIDD pre-deploys and reserves its R&D capacities to provide immediate response and action to outbreaks of emerging infectious diseases.

Business Interests

Translational medical research, Core facility support, Innovation and incubation center, Smart healthcare, Bio-cluster, BioHub Taiwan.

Contact information

Name	Jacky Chen	Christina Wei
Position	Project Manager	Project Manager
Tel	+886-2-7750-5315	+886-2-7750-5320
Email	cet252@gate.sinica.edu.tw	yuchen01@gate.sinica.edu.tw



Main Products / Services

Products

- Medical & Assistive devices
- Vaccines & Drugs
- Dietary supplements
- Advanced agricultural products

Services

- Integrated industrial, academic and medical resources
- Developing new solutions that better support public needs

Business Interests

- Collaborative R&D
- CDMO

Contact information

Name I-Jou Chen (Athena)
Position Translator
Tel +886-4-2565-8588 #1112
Email ijouchen@ctsp.gov.tw



Contact information

Name Meng-Fang Hsu

Position Specialist

Tel +886-2-2312-4058

Email mengfang@mail.coa.gov.tw

Hsin-Chuan Huang

Associate researcher

+886-2-2312-4018

hsinchuanh@mail.coa.gov.tw



Main Services

To enhance innovation and entrepreneurship for academic research

With the innovation and entrepreneurship programs, the department encourage deep technology from university to new venture, build a platform like Taiwan Tech Arena (TTA) to drive more corporate investment and international investors, offer supportive programs for startups to global exhibitions and talent exchanges.

To support academia-industry relationship

With the Academia industry collaboration programs, the department encourages businesses to participate in university-based applied research projects, promotes collaboration on highly innovative research projects, sets rules for co-ownership of research results, and establishes alternative models for technology transfer authorization, thus increasing the effectiveness of industry-academia cooperation.

To develop science parks

Under Taiwan Vision 2030, the science parks are set to strive for innovation, inclusion, and sustainability. We aim to strengthen the science parks development policies, the related regulation review and revision, science parks enterprise investment review, and talents cultivation.

Business Interests

- Innovation and entrepreneurship
- Academia-industry collaboration
- Startups
- Talent cultivation

Contact information

Name Kai-Shyr Wang
Position Section chief
Tel +886-2-2737-7818
Email kswang@most.gov.tw



Main Products / Services / Pipelines & Platforms

New drug Development

- CDMO of New Proteins and Biosimilars
- Monoclonal Antibodies and Recombinant Proteins
- Cell Sheet
- Cell therapy product CDMO
- Central Nervous System Small-molecule Drugs
- Viral vector for gene/cell therapy
- IntraOcular Lens (IOL) and Its Delivery System

High-end Medical Equipment

- Nano-Well Slide for Real-Time PCR System and Device
- Non-invasive Biochemical Analyzer, Related Consumables and Software
- Wearable Vital Sign Sensing Modules and Components
- Next Generation Biosensing System for Molecular Diagnostics
- Development of clinical test for Non-invasive cancer biomarker
- Cell and Gene Therapy Platform
- Contact-Lens-Shaped Imaging Retina Prosthesis
- Nucleic Acid Diagnostic Equipment
- Cancer Genome Profiling testing kits and analysis service
- AB-BNCT medical device
- Surgical Navigation System
- Respiratory rate monitor, apnea monitor
- Negative Pressure Sleep Apnea Treatment Device

Business Interests

IP Licensing, Collaborative R&D, CDMO

Contact information

Name Ms. Christine Huang
Tel +886-3-577-3311 #2712
Email princess@sipa.gov.tw



Main Services

The Ministry of Health and Welfare of the Republic of China (MOHW) is the Executive Yuan ministry responsible and the highest authority for the administration of the public health system, social welfare, affordable and universal health care, hospitals, pharmaceutical, immunization programs, disease prevention, supervision and coordination of local health agencies in Taiwan. The MOHW was originally established on 17 March 1971 as the Department of Health (DOH). The department was upgraded to Ministry of Health and Welfare on 23 July 2013 with the addition from the agencies in the Ministry of the Interior responsible for social welfare following restructuring of the Executive Yuan. The mission of MOHW is to promote the health and well-being of all Taiwan citizens.

Business Interests

The MOHW's diversified responsibilities include health policy planning and promotion, prevention and control of disease, food safety, drug management, social insurance and welfare, relief and protective services.

Contact information

Name	Hsien-yang Lee
Position	Researcher, Office of Science and Technology
Tel	+886-2-8590-7567
Email	schsien-yanglee0641@mohw.gov.tw



Main Services

The BioMed Commercialization Center (BMCC) , funded by the Ministry of Science and Technology (MOST), is to provide an integrated platform to overcome the bottleneck found in the development and commercialization of pharmaceuticals and medical devices for academia and industries.

Business Interests

- IP/Tech feasibility and analysis for pharmaceuticals and medical devices
- Prototyping service for pharmaceuticals and medical devices
- Marketing analysis and regulatory compliance support for pharmaceuticals and medical devices
- Accelerate commercialization for pharmaceuticals and medical devices

Contact information

Name	BioMed Commercialization Project Manager	
Position	Pharmaceuticals	Medical Device
Tel	+886-2-2652-2677	+886-3-658-8760 #2044
Email	dcc@biip-dcc.org	pcchou@biip-mdcc.org



Main Services

Products

- Dental Products Combining the Integration of Software and Hardware
- Minimally Invasive Medical Devices
- Biomedical-Grade Collagen, Wound Care Dressings, Nano Dressings, Skin External Applications and Functional Cosmeceutical Products
- Artificial Joints, Trauma, Spine and Other Orthopedic Products
- In Vitro Diagnostic Products
- Pharmaceutical Products
- Dietary Supplements
- Ophthalmic Femtosecond Laser Surgical Instruments
- Biomedical Image Detection and Intelligent Image Monitoring

Services

- Link with Academia, Research Centers and Hospitals
- Interdisciplinary Talents Training

Business Interests

Collaborative R&D, CDMO

Contact information

Name Mr. Wang, Young-Her
Position Section Chief
Tel +886-6-505-1001 #2520
Email beaniris@stsp.gov.tw



Main Services

The Taiwan Stock Exchange (TWSE) started operation on Feb. 1962. With the objective of creating a fair, efficient and safe trading environment, the TWSE operates in line with government policy to develop a healthy securities market. Products listed on the TWSE include Taiwan Depository Receipts (TDRs), Warrants, Stocks and Exchange Traded Funds (ETFs). As of 2021, there were 970 listed companies with a total market capitalization approximately US\$ 2trillion, and ranked No. 16 in the world.

TWSE, through its listing advisory guidance and market oversight functions, actively promotes sustainable operation of listed companies with a special focus on economic development, social responsibility, and environment sustainability.

Contact information

Name	Peter Chuang
Position	Associate, Foreign Listing Department
Tel	+886-2-8101-3509
Email	1020@twse.com.tw



Main Services

- Biotech Industry Promotion.
- Assist companies with various requirements for setting up business in Taipei.
- Taipei City Government established 'Taipei Municipal Self-Government Ordinance for Industrial Development', Small and Medium Enterprise of the Loan, and Young Entrepreneurs of the Loan.
- Taipei Bioinnovation Park: Industrial area for incubation centers, offices, R&D labs, and a prototyping factory, as well as multifunctional spaces for bio-tech companies.

Business Interests

- Welcome Int'l bio research unit and companies to land in Taipei.
- Well-equipped bio-cluster and IP protection enables you find partners in Taipei.

Contact information

Name Shao-Nan, Chen
Position Researcher
Tel +886-2-2720-8889 #6584
Email rn5145@mail.taipei.gov.tw



Main Services / Pipelines & Platforms

Preclinical Testing Services of Pigs and Rodents

- Biomedical device / platform
- Certification : OECD-GLP and AAALAC
- For animal safety and efficacy studies
- Comply with Good Laboratory Practice (GLP) accredited by Taiwan Accreditation Foundation (TAF)

SPF Pig Tissue Supply Platform

- Biomedical device / platform
- ISO 13485 certificated laboratory and in compliance with ISO 13485 / ISO 22442 for pig tissue supply
- Application : Production of collagen and bone meal

Recombinant Protein Production Service

- One-stop service from gene cloning to protein expression, purification, and assay development
- Gene expression systems include bacterial expression host and Yeast expression host
- Customized protein services

Biosafety Testing and Virus Validation

- Assays available for service and quality assurance
- Applications can be practicable to different stages of biopharmaceutical and other biotech products development

Contact Information

Name Dr. Shao-Wen Hung
Position Division Chief
Tel +886-37-585-930
Email 1032169@mail.atri.org.tw



Main Services / Pipelines & Platforms

Pipelines

- **FLT3 Kinase Inhibitor** : Highly selective and potent against FLT3 and FLT3 mutants with superior tolerance in preclinical tox study.
- **Raf Kinase Inhibitor** : IND ready. Highly selective, potent cytotoxicity to cancer cells with BRAF mutation.
- **Anti-CD73 Antibody** : Long-lasting inhibition to CD73 enzyme activity showing superior anti-tumor activity than the benchmark.
- **PD-L1/TIM-3/CSF-1R Antibodies** : Unique CDR sequences and different binding epitopes from competitors featuring high affinity and in vitro activity.
- **RAS-PROTAC** : Conspicuous inhibition to various KRAS mutation types with KRAS degrader.
- **Globo H/O Blocker CAR-T Cells for Solid Tumor** : Enhancement of Globo H-specific CAR-T cells activity by PD-L1 antibody to overcome PD-1/PD-L1-mediated immunosuppression in solid tumor.
- **CHO-C High Yield Protein Drug Platform** : Cell line development service with proprietary CHO-C cell lines offering high productivity and cost-effective solution to Biopharma.

Services

- Antibody Generation, Production, and Characterization.
- Small Molecule Synthesis Platform
- Preclinical Pharmacology
- Preclinical ADME / DMPK
- Drug Analysis & Formulation
- Toxicology Pilot Study & Consultation Service
- mRNA and LNP Production
- Oligonucleotide Synthesis and Production
- BD service to help in looking for license possibility, IP strategy /analysis, Market & Competitive Analysis

Business Interests

DCB is a non-profit research institute that focuses on pre-IND stage drug development. We welcome partners for cooperation to advance our pipelines to clinical trials and commercialization. We are also seeking licenses out of our high-potential targets.

Contact information

Name Joyce Tai
Position BD
Tel +886-2-7700-3800 #5240
Email pphhtai@dcb.org.tw

**ITRI**Industrial Technology
Research Institute**Industrial Technology Research
Institute**itri.org.tw/english/index.aspx

Main Services

- ITRI-501, Anti-TIGIT Monoclonal Antibody For Solid Tumor Therapy
- iKNOBEADS -An Efficient and Economic Platform for Expansion of Human Immune Cells for cell therapy
- Automatic Cell Production System
- Regulation compliant MSC cell bank and final product manufacturing technology
- Implantable transparent biomaterials application in corneal protection and reconstruction
- Novel TLR9 agonist delivery technology for cancer immunotherapy
- An oral AR/AR-V7 PROTAC-148 for the treatment with castration-resistant prostate cancer (CRPC)

Business Interests

- R&D Collaboration
- CDMO
- CRO
- Out-Licensing

Contact information

Email ITRI_BDL@itri.org.tw



Main Services

Pharmaceutical, medical devices, health products and cell culture development.

Business Interests

- Development of pharmaceutical critical platform technology
- Botanical medicine new drug/new product driving industry development
- Drug-eluting medical devices and products
- Development of soft biomedical materials
- Promotion of medical product internationalization
- Development of various analytical platform technology
- Medical technology upgrade and product quality improvement
- Medical industry talent training
- Assisting with the promotion of pharmaceutical policies
- Expanding the supply of information services

Contact information

Tel +886-2-6625-1166
Email pitdc_p@pitdc.org.tw



Main Services

- advance biomedical sciences
- promote population and individual health
- forge biotechnology and pharmaceutical development
- train and cultivate biomedical researchers

Business Interests

R&D Collaboration, Licensing

Contact information

Name Hua-Hsuan Liang
Position Acting Section Chief
Tel +886-37-206-166 #33206
Email huahsuan@nhri.edu.tw



Main Services

- Taipei Exchange (TPEX) is an integrated and multifunctional exchange founded in 1994.
- TPEX has been an official member of the World Federation of Exchanges (WFE) since 2011.
- TPEX has built an efficient fund-raising platform that supports the growth of small and medium-sized enterprises and helps those corporations become stronger.
- Our market provides a tiered structure, which ranges from the micro-enterprise supporting Go Incubation Board for Startup and Acceleration Firms (GISA), to the Emerging Stock Market (ESM) for pre-IPO companies, and on to the Mainboard (MB) for trading more established companies.
- In support of the innovative industry, TPEX has launched a new stock board named the Pioneer Stock Board (PSB) in Q3 2021. PSB has formed the ESM together with the existing Emerging Stock Board (ESB).
- This GISA to ESM to MB structure supports enterprises' growth through all their stages of development and has contributed to the strong growth of Taiwan's capital markets.

Contact information

Name Pi Ying Chen
Position Manager, Listing Examination Department
Tel +886-2-2366-6136
Email alicepchen@tpex.org.tw



Main Services

- Promoting the interests of our members
- Promoting international exchange and cooperation
- Promoting communication between government and industry
- Cultivating biotechnology industry talent
- Encouraging outstanding performance and innovation

Business Interests

BIO Asia–Taiwan

BIO Asia–Taiwan is Asia's largest biotech networking event, and is jointly organized by the global Biotechnology Innovation Organization (BIO) and the Taiwan Bio Industry Organization (Taiwan BIO). The BIO Asia–Taiwan International Conference and Exhibition was held for the first time in 2019. An endorsement of Taiwan's standing as a leading Asian biomedical industry hub, the gathering was a resounding success.

Contact information

Name Mia Tsai
Position Marketing Specialist
Tel +886-2-2783-6028 #13
Email mia@taiwanbio.org.tw



Main Services

Founded in 1970, TAITRA is Taiwan's foremost nonprofit trade promoting organization. Sponsored by the government and industry organizations, TAITRA assists enterprises to expand their global reach. Headquartered in Taipei, TAITRA has a team of 1,300 specialists and operates 5 local offices in Taoyuan, Hsinchu, Taichung, Tainan and Kaohsiung as well as 60+ branches worldwide. Together with Taipei World Trade Center (TWTC) and Taiwan Trade Center (TTC), TAITRA has formed a global network dedicated to promoting world trade.

Main Services

- Global Marketing
- Taiwan Industry Enhancement Project
- Promoting the Service Sector
- Market Research and Publication
- Digital and E-commerce Marketing
- Gaining Trade Insights with Trade Data Analytics
- International Trade Institute
- Taiwan International Trade Shows
- Exhibition and Convention Venues
- External Relations

Contact information

Tel +886-2-2725-5200
Email taitra@taitra.org.tw


Medical Micro Molding Service

ISO 13485 certified
contract manufacturing of
medical micro components,
with **CDMO** capabilities.
Your offshore quality molding
partner.




Microneedle patch for drug delivery

Partnering with pharma to develop solid, hollow and absorbable microneedle patch. Providing turnkey production line and validation services for large molecule absorption.



Microfluidic chip development

PDMS or thermoplastic microfluidic chips economically manufactured by precision tooling or LIGA, from prototyping to mass production.



Micro Injection Molding

Precision medical molding / insert molding / LSR / TPE for parts from 10 to 0.0001g in ISO 13485 certified, Class 10000 clean room facility. Design services include Part / Mold design, DFM/CAE, Quality plan.





Your Best Partner In Asia

One-Stop-Shop for Taiwan's Biomedical Industry



Biotechnology and Pharmaceutical Industries Promotion Office, MOEA

Room A, 17F, No.3, Park St, Nangang District, Taipei 115, Taiwan

Tel: +886-2-2655-8135 Fax: +886-2-2655-8134

E-Mail: services@biopharm.org.tw Web: <http://www.biopharm.org.tw>

